Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Single Mouse Trial Platform for Evaluation of Novel Agents in Acute Lymphoblastic Leukemia By the Pediatric Preclinical Testing Consortium

Richard B. Lock, PhD, Kathryn Evans, Tara Pritchard, Cara Toscan, Chelsea Mayoh, Beverly Teicher, Raushan T Kurmasheva, Peter J Houghton, Malcolm Smith, MD PhD

Blood (2018) 132 (Supplement 1): 4010.

https://doi.org/10.1182/blood-2018-99-113207

Published: 2018

Journal Articles

Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project.

Jinghui Zhang, Ph.D., Charles G. Mullighan, MBBS(Hons), MSc, MD, Richard C. Harvey, PhD, Kenneth E Buetow, Ph.D, William L. Carroll, MD, I-Ming Chen, MS, Meenakshi Devidas, PhD, Michael Edmonson, Daniela Gerhard, PhD, Ying Hu, PhD, Mignon L. Loh, MD, Letha A Phillips, BS, Gregory H Reaman, M.D., Mary V. Relling, PharmD, Malcolm Smith, MD, PhD, James R. Downing, MD, Cheryl L. Willman, MD, Stephen P Hunger, MD

Blood (2009) 114 (22): 85.

https://doi.org/10.1182/blood.V114.22.85.85

Published: 2009

Journal Articles

Deletion of IKZF1 (Ikaros) Predicts Poor Outcome and Impaired Maturation in B-Progenitor Acute Lymphoblastic Leukemia

Blood (2008) 112 (11): 427.

https://doi.org/10.1182/blood.V112.11.427.427

Published: 2008

Journal Articles

Use of Genomic Technologies to Identify Novel Genetic Abnormalities and Therapeutic Targets In Acute Lymphoblastic Leukemia.

Cheryl L. Willman, MD, Huining Kang, PhD, Richard C. Harvey, PhD, I-Ming Chen, DVM, MS, Charles Mullighan, MD, James R. Downing, MD, Mary V. Relling, PharmD, Jinghui Zhang, PhD, Daniela Gerhard, PhD, Malcolm Smith, MD, PhD, Kevin K. Dobbin, PhD, Gregory Reaman, MD, Stephen Hunger, MD

Blood (2008) 112 (11): sci-8.

https://doi.org/10.1182/blood.V112.11.sci-8.sci-8

Published: 2008

Journal Articles

Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Children’s Oncology Group (COG) Study.

Richard C. Harvey, PhD, I-Ming Chen, MS, Kerem Ar, MS, Stephen P. Hunger, MD, Mignon Loh, MD, Eric C. Larsen, MD, Meenakshi Devidas, PhD, Elizabeth Raetz, MD, Gregory Reaman, MD, William L. Carroll, MD, Naomi Winick, MD, Malcolm Smith, MD, PhD, Kevin K Dobbin, PhD, Cheryl L. Willman, MD

Blood (2008) 112 (11): 2256.

https://doi.org/10.1182/blood.V112.11.2256.2256

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Single Mouse Trial Platform for Evaluation of Novel Agents in Acute Lymphoblastic Leukemia By the Pediatric Preclinical Testing Consortium

Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project.

Deletion of IKZF1 (Ikaros) Predicts Poor Outcome and Impaired Maturation in B-Progenitor Acute Lymphoblastic Leukemia

Use of Genomic Technologies to Identify Novel Genetic Abnormalities and Therapeutic Targets In Acute Lymphoblastic Leukemia.

Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Children’s Oncology Group (COG) Study.

Email alerts

ASH Publications

American Society of Hematology

Update search

A Single Mouse Trial Platform for Evaluation of Novel Agents in Acute Lymphoblastic Leukemia By the Pediatric Preclinical Testing Consortium

Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project.

Deletion of IKZF1 (Ikaros) Predicts Poor Outcome and Impaired Maturation in B-Progenitor Acute Lymphoblastic Leukemia

Use of Genomic Technologies to Identify Novel Genetic Abnormalities and Therapeutic Targets In Acute Lymphoblastic Leukemia.

Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Children’s Oncology Group (COG) Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only